Journal article icon

Journal article

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Abstract:

BACKGROUND: Previous trials of interferon beta in multiple sclerosis (MS) have shown efficacy, but the degree of clinical benefit remains uncertain, and the optimum dose is not known. We undertook a double-blind, placebo-controlled study in relapsing/remitting MS to investigate the effects of subcutaneous interferon beta-1a. METHODS: 560 patients with Kurtzke expanded disability status scale (EDSS) scores of 0-5.0, from 22 centres in nine countries, were randomly assigned subcutaneous recombi...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Neuroscience, WTC Human Genetics
Expand authors...
Journal:
Lancet
Volume:
352
Issue:
9139
Pages:
1498-1504
Publication date:
1998-11-05
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
URN:
uuid:61d8908f-d676-4725-b673-220d6d81871c
Source identifiers:
14327
Local pid:
pubs:14327

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP